Vitamin K2
CANCER: A 2006 pilot study found that menatetrenone, a vitamin K2 analog, significantly reduced recurrence rates of hepatocellular carcinoma (HCC) at 12, 24, and 36 months and suggested potential benefits on survival, compared to a control group (P = 0.0002). A 2012 prospective randomized controlled trial showed that menatetrenone moderately suppressed HCC recurrence after hepatectomy, particularly in patients with normal preoperative Des-γ-carboxy-prothrombin levels (p=0.060). Vitamin K2 (3-10 μM) treatment in vitro induced apoptosis in leukemic blast cells from 15 MDS patients , with a more significant effect on blastic cells than mature myeloid cells or CD3-positive lymphoid cells, suggesting potential for MDS treatment in blastic transformation ( 1998 ) Administration of menatetrenone (45 mg daily) improved pancytopenia and transfusion-dependence in an 80-year-old MDS patient, suggesting potential for restoring hematopoiesis in MDS patients by inducing differentiation ( 1999 )